A Breakthrough Spatial Technology for Cancer Research

The G4X Spatial Sequencer is a high-throughput in situ sequencing platform.  With simultaneous transcriptomic, proteomic, and fH&E analysis from FFPE samples, the G4X is a high-impact multiomic platform for cost-effective single-cell cancer research.

Amplify Your Research with a $50,000 G4X Spatial Sequencing Grant

Generate powerful multiomic data from your samples with in situ sequencing and imaging on the G4X Spatial Sequencer.  Three recipients of the G4X Research Grant will receive $50,000 of spatial sequencing services, good for 40cm2 of imaging or applicable to a larger project. Recipients also eligible to recieve a travel grant to present the data at a conference.

Important Dates

Application Opens


Application Closes


Grants Awarded

See The Data from AGBT

Sequencing-Based High-Throughput Imaging of Proteins and RNA in FFPE Tissue Sections

Spatial Technology Access Services

Want to access tomorrow’s high-throughput in situ sequencing technology today with cost-effective subcellular spatial multiomic services for your cancer research studies? Meet our team of experts and get involved today.

Connect With Us at AACR in San Diego

Demo the G4X, see the data, and meet our team of experts in San Diego at American Association for Cancer Research (AACR) 2024 to learn more about how the G4X can transform your research.

G4X Research Grant Inquiry

Please provide your information and a member of the Singular Genomics team will be in contact to provide more details about the research grant.

Download G4X Poster

Please provide your information to download the poster.

Technology Access Services Information

Please provide your information and a member of the team will be in contact to provide more information on the Technology Access Services.

Connect with Us at AACR

Please provide your information and a member of the Singular Genomics team will be in contact to set up a meeting.

Drew Spaventa

Drew founded Singular Genomics in 2016 serving as the CEO and Chairman. Drew is a serial entrepreneur and venture investor in the biotech industry and has been involved in the founding of several successful companies. Prior to Singular Genomics, Drew founded Truvian Sciences, a low volume blood testing technology aimed at making routine blood tests easier, less invasive, and more affordable. Drew was also involved in the founding of Aspen Neurosciences where he co-led the seed financing and helped assemble a world-class team to combat Parkinson’s Disease using a patient’s own stem cells. Drew was also a seed investor and held an operating role in Edico Genome which sold to Illumina in 2018.

Drew received an MBA from the Rady School of Management at the University of California, San Diego and a BA in Political Science and International Relations from the University of California, San Diego.

Max Reads Application Note